- Home
- LVLU vs GDTC Comparison
LVLU vs GDTC Comparison
Compare LVLU & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- GDTC
- Stock Information
- Founded
- LVLU 1996
- GDTC 2018
- Country
- LVLU United States
- GDTC Singapore
- Employees
- LVLU N/A
- GDTC N/A
- Industry
- LVLU Catalog/Specialty Distribution
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- GDTC Health Care
- Exchange
- LVLU Nasdaq
- GDTC Nasdaq
- Market Cap
- LVLU 28.6M
- GDTC 29.4M
- IPO Year
- LVLU 2021
- GDTC 2023
- Fundamental
- Price
- LVLU $0.46
- GDTC $2.70
- Analyst Decision
- LVLU Hold
- GDTC Buy
- Analyst Count
- LVLU 3
- GDTC 1
- Target Price
- LVLU $1.58
- GDTC $5.00
- AVG Volume (30 Days)
- LVLU 17.9K
- GDTC 11.3K
- Earning Date
- LVLU 03-27-2025
- GDTC 01-01-0001
- Dividend Yield
- LVLU N/A
- GDTC N/A
- EPS Growth
- LVLU N/A
- GDTC N/A
- EPS
- LVLU N/A
- GDTC N/A
- Revenue
- LVLU $324,699,000.00
- GDTC $330,254.00
- Revenue This Year
- LVLU N/A
- GDTC $14.71
- Revenue Next Year
- LVLU $1.72
- GDTC N/A
- P/E Ratio
- LVLU N/A
- GDTC N/A
- Revenue Growth
- LVLU N/A
- GDTC N/A
- 52 Week Low
- LVLU $0.46
- GDTC $1.20
- 52 Week High
- LVLU $1.99
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- LVLU 11.81
- GDTC 45.20
- Support Level
- LVLU $0.48
- GDTC $2.42
- Resistance Level
- LVLU $0.77
- GDTC $2.80
- Average True Range (ATR)
- LVLU 0.06
- GDTC 0.17
- MACD
- LVLU -0.02
- GDTC -0.02
- Stochastic Oscillator
- LVLU 3.46
- GDTC 46.15
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.